Table 3 Univariate and multivariate logistic regression models of 3-month functional independence with calprotectin and other baseline characteristics

Age (per 10-year increase)

0.57 (0.46–0.71)

< 0.001

0.64 (0.47–0.88)

0.006

Sex (female)

0.67 (0.43–1.06)

0.089

0.80 (0.43–1.52)

0.502

Weight (kg)^a

0.87 (0.26–2.93)

0.827

Hypertension

0.74 (0.45–1.21)

0.232

Type 2 diabetes

0.87 (0.53–1.42)

0.572

Dyslipidemia

0.96 (0.61–1.50)

0.852

eGFR < 45 mL/min/1.73 m²

0.44 (0.20–0.97)

0.041

0.70 (0.24–2.01)

0.508

SBP at admission^a (per 10-mmHg increase)

1.40 (0.36–5.36)

0.628

DBP at admission (per 10-mmHg increase)

1.01 (0.89–1.16)

0.830

Serum glucose at admission (mg/dL)^a

0.34 (0.16–0.71)

0.004

0.28 (0.10–0.74)

0.011

Neutrophil count (_xmm3)^a

0.37 (0.20–0.66)

0.001

^b

Lymphocyte count (_xmm3)^a

2.40 (1.50–3.86)

< 0.001

^b

NLR^a

0.44 (0.31–0.62)

< 0.001

0.62 (0.38–1.01)

0.055

C-reactive protein (mg/L)^a

0.64 (0.53–0.78)

< 0.001

0.90 (0.68–1.18)

0.445

Calprotectin μg/mL^a

0.49 (0.34–0.70)

< 0.001

1.04 (0.62–1.75)

0.877

 8–14 (vs 0–7)

0.16 (0.08–0.30)

< 0.001

0.12 (0.05–0.28)

< 0.001

 > 14 (vs 0–7)

0.12 (0.07–0.21)

< 0.001

0.11 (0.04–0.31)

< 0.001

ASPECTS at baseline ≥ 7

18.95 (2.37–151.57)

0.006

5.03 (0.46–54.6)

0.185

Baseline mRS score ≤ 1

2.39 (1.40–4.06)

0.001

1.63 (0.80–3.30)

0.179

Intravenous thrombolysis

0.47 (0.30–0.74)

0.001

1.37 (0.64–2.93)

0.418

Endovascular treatment

0.51 (0.29–0.89)

0.018

1.84 (0.67–5.04)

0.237

Hemorrhagic transformation

0.13 (0.06–0.28)

< 0.001

0.23 (0.08–0.66)

0.007

Cardioembolic stroke

0.48 (0.32–0.73)

< 0.001

1.60 (0.83–3.08)

0.161